10:45 - 10:50 amSaturday, September 26
Lower Lobby - West
Panorama - Cognitive mobile healthcare
Lower Lobby - West
Panorama - Cognitive mobile healthcare
Pathway Genomics
The proper goal for any healthcare delivery system should be to improve the value of care delivered to patients. It is not the number of different services provided, or the volume of services delivered,... Read more


The proper goal for any healthcare delivery system should be to improve the value of care delivered to patients. It is not the number of different services provided, or the volume of services delivered, that matters. It is the value of the care that is important. There are two factors that substantially contribute to decreased value in healthcare: unstructured health data and health care costs.

The Data Problem

Every two years, the world’s database doubles, and medical information, specifically, doubles every three years. By 2020, global healthcare data will double every three days, with 80% of the data being unstructured.[1] Healthcare costs in the United States currently exceed 17% of the GDP and continue to rise – patients bear little responsibility for the cost of healthcare services they demand. 

In general, medicine – and precision medicine – is a big data and systems problem, with many different types of healthcare data, such as lab results, BMI, genetic tests, and insurance information, needing to be collected and intelligently codified on an individual user basis. But data is worthless unless it can be analyzed and acted on. Patients and physicians deserve accurate and actionable recommendations on this healthcare data to truly personalize medicine.

The Cost Problem

A powerful driver of value in health care is that better outcomes often go hand-in-hand with lower total care cycle costs. Spending more on prevention, early detection and better diagnosis of disease, for example, spares patients suffering and often leads to less complex and less expensive care later. As an example, the use of telemedicine in the UK has led to a 45% drop in mortality rates, and a 20% reduction in emergency hospital admissions.[2]

The Solution: Natural Language Processing Artificial Intelligence

With the above caveats in mind, the use of artificial intelligence (AI) that can read unstructured data automatically, collate and make recommendations on the myriad of healthcare data streams (cognitive medicine) will dramatically impact medical care. Natural language processing (NLP) AI, such as IBM Watson, has already shown utility in oncology programs at Memorial Sloan Kettering and other institutions. 

Dr. Nova is currently the chief medical officer of Pathway Genomics, and was a founding team member of the company. He is the inventor of the entire nutrition (Pathway FIT/Healthy Weight), Cardiac, and Mental Health line of products for Pathway; and also the Pathway-IBM/Watson Big Data-Deep Learning mobile application: Panorama. Dr Nova has also executed major corporate alliances with companies like Medco/ESI, PepsiCo, DASA (Brazil), Biogenetika (Brazil), Achibadem (Turkey), IHH/Parkway (Singapore), IBM, Florida Hospital Group, Equinox Health, and many others. His scientific career began as a research associate at the Salk Institute in the laboratory of Nobel Laureate Roger Guillemin, where he studied the genetics and proteomics of human growth factors and cancers. Michael was the founder and CEO of Discovery Partners Inc. (Nasdaq: DPII), which completed a successful $150M IPO and marketed wireless drug discovery technology and radiofrequency combinatorial chemistry to large pharmaceutical companies. Intellectual property developed by Dr. Nova at DPII included the original “barcode on bead” patents used by many diagnostic and DNA companies. He then founded the wireless sensory network company Graviton, where he was responsible for raising $60 million in capital from venture groups such as Kleiner Perkins, InQtel and large corporations such as Motorola and Qualcomm. Dr. Nova is also a 2005 World Economic Forum Technology Pioneer Award Winner; and the physician of record on the first person ever to have their entire genome sequenced by Illumina (2009). Dr. Nova has over 30 issued, and 35 pending patents; and he has numerous publications in peer-reviewed journals. With degree’s in biochemistry, physics, and medicine, Dr. Nova is a Board-certified Dermatologist and Dermatopathologist licensed in California. In his minimal spare time, Michael likes to surf big waves in Indonesia and Mexico, and he also helped build a WHO-sanctioned basic care clinic in the Fijian town of Nabila.

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search